Trial site
Clinstile, S.A. de C.V.
Mexico City, 06700, MexicoNot linked to an institution yet
- 19running trials
- 1closed trial
The trials here
What the 20 trials at this site are about, from their registry records.
- Phase
- Phase 313 trials
- Phase 25 trials
- Phase 2/32 trials
- Status
- Active, not recruiting11 trials
- Recruiting6 trials
- Enrolling by invitation2 trials
- Completed1 trial
- Lead sponsor
- Hoffmann-La Roche7 trials
- Biogen3 trials
- Biohaven Therapeutics Ltd.2 trials
- Alfasigma S.p.A.1 trial
- Amgen1 trial
- and 6 more
Running trials
Recruiting
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
NCT06899126· Phase 3· Daiichi Sankyo· Source
Recruiting
A Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis (RMS)
NCT07161258· Phase 2· Hoffmann-La Roche· Source
Recruiting
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
NCT06641466· Phase 3· Pfizer· Source
Recruiting
A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
NCT06747949· Phase 3· Amgen· Source
Active, not recruiting
A Study of Obexelimab in Patients With Systemic Lupus Erythematosus
NCT06559163· Phase 2· Zenas BioPharma (USA), LLC· Source
Enrolling by invitation
Long-term Safety and Tolerability of BHV-7000
NCT06443463· Phase 2· Biohaven Therapeutics Ltd.· Source
Active, not recruiting
Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
NCT06309966· Phase 2/3· Biohaven Therapeutics Ltd.· Source
Active, not recruiting
A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus
NCT05672576· Phase 3· Viatris Innovation GmbH· Source
Active, not recruiting
The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)
NCT05540327· Phase 2· Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany· Source
Active, not recruiting
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
NCT05531565· Phase 2/3· Biogen· Source
Enrolling by invitation
A Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effects on Symptoms in Adults With Systemic Lupus Erythematosus (SLE)
NCT05352919· Phase 3· Biogen· Source
Active, not recruiting
A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)
NCT05123703· Phase 3· Hoffmann-La Roche· Source
Recruiting
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
NCT05039619· Phase 2· Hoffmann-La Roche· Source
Recruiting
Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults
NCT05219617· Phase 3· SK Life Science, Inc.· Source
Contact: Sandra Quinones, MD (principal investigator)
Active, not recruiting
A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
NCT04895241· Phase 3· Biogen· Source
Active, not recruiting
Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
NCT04586023· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)
NCT04548999· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis
NCT04544449· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis
NCT03523858· Phase 3· Hoffmann-La Roche· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error